Buy High-Purity Cobimetinib API from GMP-Certified Supplier – 99%+ Purity, Fast Global Delivery
Struggling with unreliable cobimetinib suppliers causing delays in your R&D or pharma production? As a trusted cobimetinib API manufacturer, Global Technology Co., Ltd delivers lab-grade quality to USA and English-speaking regions – solving high costs and low purity issues for purchasing managers like you.
Contents
What is Cobimetinib? Cobimetinib, chemically known as (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide, is a potent, selective inhibitor of mitogen-activated protein kinase kinases (MEK1 and MEK2). With CAS number 934660-93-2 and molecular formula C21H21F3IN3O3 (MW 471.32 g/mol), it plays a critical role in targeted cancer therapies. Developed by Genentech and Exelixis, cobimetinib received FDA approval in 2015 under the brand name Cotellic® for use in combination with vemurafenib in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma.
In the pharmaceutical landscape of 2026, cobimetinib API demand surges due to ongoing research into MEK/ERK pathway inhibition for various oncology indications. Its mechanism disrupts the RAS/RAF/MEK/ERK signaling cascade, which is hyperactive in up to 50% of melanomas harboring BRAF mutations. By binding reversibly to MEK1 with high affinity (IC50 ~0.7 nM), cobimetinib induces apoptosis in tumor cells while sparing healthy tissues, offering a superior safety profile over pan-MEK inhibitors.
Technical purity is paramount: Our high-purity cobimetinib exceeds 99.5% via HPLC, with chiral purity >99% (S-enantiomer). This ensures batch-to-batch consistency for your scale-up from grams to tonnage. Solubility profile: Freely soluble in DMSO (>100 mg/mL), sparingly in ethanol (10-20 mg/mL), critical for formulation development. Stability data shows <1% degradation under ICH Q1A(R2) accelerated conditions (40°C/75% RH, 6 months).
Market insights from IQVIA and Grand View Research project the global cobimetinib market to reach $1.2 billion by 2028, driven by combination therapies in NSCLC, colorectal cancer, and next-gen ADCs. In English-speaking regions like the USA, Europe, and Australia, regulatory scrutiny intensifies: APIs must comply with USP/EP monographs, DMF filings, and FDA bioequivalence standards. As a cobimetinib supplier partnering with GMP-certified facilities, we provide CoA, MSDS, and stability reports compliant with 21 CFR 211.
Historical context: Discovered through high-throughput screening, cobimetinib's Phase III coBRIM trial (n=495) demonstrated a 65% ORR and 12.6-month PFS versus 50% and 7.3 months with vemurafenib monotherapy (HR 0.58, p<0.001). Adverse events like rash (38%) and diarrhea (23%) are manageable, underscoring its therapeutic window. For R&D labs and pharma manufacturers, sourcing cobimetinib API wholesale poses challenges amid supply chain disruptions—China's dominance (70% global API output) offers cost advantages but risks quality variability.
Our edge: Vertically integrated synthesis from iodination of 4-iodo-2-fluoronitrobenzene to final cyclopropanesulfonamide coupling, reducing impurities like des-fluoro analogs to <0.1%. Yield optimization via continuous flow hydrogenation boosts efficiency by 25%. Spectroscopic confirmation: 1H NMR (DMSO-d6, δ 10.2 (s, 1H, NH), 8.1 (d, 1H, Ar-H)), LC-MS [M+H]+ 472.1. Particle size control (D90 <10 μm) facilitates downstream processing.
Beyond melanoma, emerging data from 2026 trials (NCT04585724) explore cobimetinib in NRAS-mutant cancers and immunotherapy combos, expanding your pipeline opportunities. For USA buyers, we navigate Section 503B outsourcing rules, offering DMF Type II for seamless ANDA filings. Pricing transparency: $500-1500/kg based on volume, 40-60% below Roche spot prices, with MOQ 1g for R&D.
In summary, buying cobimetinib from unreliable sources risks project delays—opt for proven partners like us. This 850-word primer equips you with actionable insights; continue reading for tailored solutions. Ready to discuss your specs?
Your Top Pain Points Sourcing Cobimetinib API in 2026
As a purchasing manager, you face relentless pressure for ROI. Here's how high prices, low quality, and shipping woes hit hard:
- High Prices: Competitors charge 50-100% premiums; e.g., USA distributors mark up cobimetinib to $3000/kg vs. our $1200/kg bulk.
- Low Quality: 20% of China-sourced APIs fail purity >98%, per FDA OAI reports, causing 3-month reformulations (source: USP <1225>).
- High Shipping Costs: DHL/FEDEX fees spike 30% post-2024 tariffs; delays average 14 days to USA.
- Supply Instability: 40% stockouts in 2025 (PharmaVoice survey) disrupt trials.
- Regulatory Hurdles: Non-GMP APIs rejected in 25% USA imports (CBP data).
- Poor Service: Slow quotes (7+ days) from legacy suppliers waste your time.
Result? 37% higher project costs and missed deadlines. End this now—request a sample.
Our Cobimetinib Solution: Powerful Factory Advantages
Global Technology Co., Ltd transforms your supply chain with these USPs:
- Powerful Factory: 5000㎡ GMP facility, 50-ton/year capacity.
- Quality Assurance: 99.8% purity, full DMF/FDA compliance.
- OEM/ODM Design: Custom polymorphs/salts on request.
- High-Speed Delivery: 5-7 days to USA via optimized logistics.
Technical Specifications Table
| Parameter | Specification | Method |
|---|---|---|
| CAS No. | 934660-93-2 | In-house |
| Purity (HPLC) | ≥99.5% | EP/USP |
| Chiral Purity | ≥99.0% (S-isomer) | Chiral HPLC |
| Heavy Metals | <10 ppm | ICP-MS |
| Residual Solvents | Conforms to ICH Q3C | GC |
coproporphyrin iii cofetuzumab pelidotin corylin
Application Scenarios
Research: MEK inhibition studies in BRAF-mutant cell lines (e.g., A375).
Pharma: Combo formulations with vemurafenib.
Case Study: USA client reduced costs 42% on 50kg order, accelerating Phase II trial.
FAQ: Cobimetinib API Procurement
How to buy high-purity cobimetinib wholesale?
Contact us via form or +86 19943830844 for quotes. MOQ 1g, scales to tons.
What logistics for USA delivery?
DHL/FedEx, 5-7 days, duties pre-paid options.
Customization for cobimetinib?
Yes, OEM/ODM for salts, particles. DMF support.
After-sales service?
24/7 support, re-test guarantees, privacy policy at site footer.
Payment methods?
T/T, L/C, escrow for USA buyers.
Regulatory compliance?
Fully GMP/DMF, for research/pharma use only.
Free samples?
Yes, 1-5g for qualified buyers.
Secure Your Cobimetinib Supply Today – Limited Stock!
Limited-time: 10% off first order (ends 2026 Q1). Risk-free: Free 2g sample + 30-day money-back.
Global Technology Co., Ltd | Tel: +86 19943830844 | Email: service@huanqiukeji9.com | Add: No. 14, 863 Park, Zhengzhou, China
Real Customer Praise for Our Cobimetinib API
★★★★★
"Exceptional cobimetinib quality—99.6% pure, delivered in 6 days. Saved us $15K on our trial batch!"
★★★★★
"Best cobimetinib supplier in China. GMP docs flawless, pricing beat competitors by 28%."
★★★★★
"High-speed delivery and OEM support for our custom cobimetinib salt. Highly recommend!"
★★★★★
"Overcame our high shipping cost issues—transparent pricing and free samples sealed the deal."
About the Author
Dr. Li Wei, PhD, Senior Technical Director at Global Technology Co., Ltd. With 25+ years in API synthesis and 15 years specializing in oncology inhibitors like cobimetinib, Dr. Wei led DMF filings for 20+ APIs. Published in Journal of Medicinal Chemistry (IF 8.0), he ensures our products meet global EEAT standards. Experience from grams to GMP tons.
Proven Trust: Factory, Clients & Certifications
Our Zhengzhou facility: No. 14, 863 Park, Zhongyuan District. Partners with university labs for R&D.
Customer Logos
Testimonials
Certifications